FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
The FDA approved bepirovirsen with existing antiviral therapy for a defined group of adults with chronic hepatitis B.
TL;DR
- The FDA approved Hibsago (bepirovirsen) with existing antiviral therapy for certain adults with chronic hepatitis B who do not have cirrhosis.
- The agency said 24% of treated patients in two trials met criteria to stop their existing medicine, compared with none receiving placebo.
- The label includes a boxed warning for serious liver reactions and low platelet counts; the approval does not apply to all people with hepatitis B.
The FDA said it approved Hibsago (bepirovirsen), in combination with existing antiviral therapy, for certain adults with chronic hepatitis B who do not have cirrhosis. Eligible patients must have taken antiviral therapy for at least six months and meet specified viral-marker criteria. [1] [2]
The agency described Hibsago as the first FDA-approved antisense oligonucleotide for chronic hepatitis B. It is administered by injection for up to 24 weeks alongside existing medicine, which patients continue for at least 24 weeks after the last Hibsago dose. [1]
Across the two trials cited by FDA, 24% of patients receiving Hibsago met requirements to stop their existing medicine, compared with none receiving placebo. Twenty-four weeks after stopping all hepatitis B treatment, 19% still had controlled virus with hepatitis B surface antigen undetectable. [1] [2]
The FDA label carries a boxed warning for serious liver reactions and low platelet counts, as well as other warnings. The approval is limited to the labeled patient group, and the long-term durability of treatment-free control remains a question for follow-up evidence. [1] [2] [3]
Why it matters
The decision introduces an antisense option into a treatment area where many patients have relied on long-term suppression. Its restricted eligibility, required combination therapy and safety monitoring define how narrowly the evidence can be applied.
Editor's note
Regulatory details and trial percentages are taken from FDA materials; no patient-specific treatment conclusions are implied.